Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
In the key Phase 3 ATTAIN-1 trial published in the New England Journal of Medicine in 2025, once-daily orforglipron 36 mg produced mean body weight reductions of 11.2% at 72 weeks in adults with obesity, with nearly 55% of participants achieving at least 10% weight loss and 36% achieving 15% or more
Liquids and multi-dose bottles are particularly vulnerable
The graphic below is from CMS (you must check off all 4 boxes to qualify)
Significant metabolic changes and hormonal adaptations occurring during rapid weight reduction may also shift hair follicles into a resting phase, leading to temporary shedding known as telogen effluvium
Supports antioxidant defenses and overall wellness
US$ 22.50
US$ 26.13
US$ 20.64
US$ 26.07
